Avalo Therapeutics (AVTX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Jun, 2026Opening remarks and agenda
Chairman welcomed participants and introduced the virtual format for the meeting.
CEO called the meeting to order and introduced board members, management, legal counsel, and auditors present.
Agenda and rules of conduct were outlined, with instructions for submitting questions and voting procedures.
Board and executive committee updates
Board members and key executives, including legal and accounting representatives, were introduced.
Shareholder proposals
Three proposals were presented: election of seven directors, approval of an amendment to the Employee Stock Purchase Plan, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Avalo Therapeutics
- Strong Phase 2 data and $405M equity raise support Phase 3 advancement and robust liquidity.AVTX
Q2 2026 - Positive Phase 2 results for abdakibart in HS position the pipeline for Phase 3 and market growth.AVTXCorporate presentation
- Abdakibart achieved leading Phase 2 efficacy and safety in HS, with Phase 3 planned for 2027.AVTXCorporate presentation
- Resale of 128,189 shares by former AlmataBio holders; no proceeds to company; lead drug advances to Phase 3.AVTXRegistration filing
- Abdakibart achieved robust efficacy and safety in HS, supporting advancement to Phase 3.AVTXCorporate presentation
- Strong Phase 2 data and $405M equity raise position the lead asset for pivotal Phase 3 trials.AVTXQ1 2026
- Virtual meeting on June 2, 2026, covers director elections, plan amendment, and auditor ratification.AVTXProxy filing
- Shareholders will vote on board elections, compensation plans, and auditor ratification at the virtual meeting.AVTXProxy filing
- Abdakibart targets IL-1β in HS, aiming for best-in-class efficacy with phase 2 data due Q2 2026.AVTXCorporate presentation